Ascend Announces Exciting New Executive Leadership Team

Ascend Advanced Therapies has strengthened its leadership team with two key appointments. Scott Broughton steps in as Chief Commercial Officer, while Michael Pinaud takes on the role of Senior Vice President of Business Operations. These strategic hires are pivotal as Ascend continues its swift growth as a gene-to-GMP CDMO.

Mike Stella, CEO of Ascend mentioned, “We have built Ascend drawing on experience in early AAV discovery and the evolution of other modalities. To ensure that we meet our goals of unrivalled transparency and collaboration internally and externally, we need the right experienced resources. This is why I am thrilled to bring in two seasoned industry veterans that understand what it takes to Aim Higher for the industry.”

New CCO, Scott Broughtone, said in a statement, “For many years there has been a common thread to deliver more cost effective and quality drugs to patients. It is great to be at Ascend where we can leverage vast expertise that has and will further empower innovators and existing biotech’s who need to validate and commercialize concepts. I see Ascend’s primary focus of being a CMC partner as the key to delivering on the industry’s common goals and building long term relationships.”

 Michael Pinaud, Senior Vice President of Business Operations said, “When I started in biotech, I had a CEO tell me that I would never want to leave this field, and I never have. I see great value in helping change patient lives, which translates into a feeling of deep responsibility to always be improving on operational performance. There is intrinsic value in what Ascend is bringing to the market, with a truly experienced team. Many resources have been invested into a strong foundation of capabilities and expertise that supports customers from gene to GMP as they look to bring life changing therapies to the clinic.”